Related Experiment Video
Updated: Jul 31, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar
Rahul Gupta1, Muling Lin2, Anila Mehta3
1Department of Cardiology, Lehigh Valley Heart and Vascular Institute, Lehigh Valley Health Network, Allentown, PA.
Insights
Vorapaxar, a novel antiplatelet, reduces thrombotic events in Acute Coronary Syndrome (ACS) patients. However, its use increases bleeding risk, requiring careful consideration for optimal patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Acute Coronary Syndrome (ACS) encompasses conditions like unstable angina and myocardial infarction, necessitating urgent treatment to reduce morbidity and mortality.
- Current ACS management relies on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel.
- Emerging therapies aim to improve outcomes for ACS patients.
Purpose of the Study:
- To evaluate the efficacy and safety of Vorapaxar, a novel antiplatelet agent, in preventing recurrent ischemic events in patients with a history of myocardial infarction or peripheral arterial disease.
- To analyze subgroup data from clinical trials (TRA 2°P-TIMI 50 and TRACER) to identify patient populations who may benefit from Vorapaxar.
- To highlight the need for ongoing research and clinical trials to fully ascertain Vorapaxar's utility.
Main Methods:
- Review of findings from the TRA 2°P-TIMI 50 trial, which led to FDA approval of Vorapaxar.
- Subgroup analysis of the TRA 2°P-TIMI 50 and TRACER trials to assess Vorapaxar's efficacy in specific patient groups.
- Examination of Vorapaxar's mechanism of action as a protease-activated receptor-1 (PAR-1) antagonist, inhibiting thrombin-mediated platelet aggregation.
Main Results:
- Vorapaxar is FDA-approved for reducing thrombotic cardiovascular events when used with aspirin and/or clopidogrel in patients with a history of myocardial infarction or peripheral arterial disease.
- A significant increase in bleeding risk was observed with Vorapaxar use.
- Subgroup analyses suggest potential benefits of Vorapaxar in patients with peripheral artery disease, coronary artery bypass grafting, and ischemic stroke.
Conclusions:
- Vorapaxar offers a novel therapeutic option for specific ACS patient populations, particularly those with a history of myocardial infarction or peripheral arterial disease.
- The increased bleeding risk associated with Vorapaxar necessitates careful patient selection and risk-benefit assessment.
- Further clinical trials are warranted to confirm Vorapaxar's efficacy and safety in diverse patient groups and specific conditions like peripheral artery disease, post-coronary artery bypass grafting, and ischemic stroke.
Abstract:
Acute Coronary Syndrome (ACS) is a term that describes pathologies related to myocardial ischemia, and is comprised of unstable angina, non-ST elevation myocardial infarction, and ST elevation myocardial infarction. Urgent management of ACS is typically necessary to prevent future morbidity and mortality. Current medical recommendations of ACS management involve use of dual antiplatelet therapy, typically with aspirin and clopidogrel. However, newer therapies are being designed and researched to improve outcomes for patients with ACS. Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events. It has been Food and Drug Administration approved for reduction of thrombotic cardiovascular events in patients with a history of MI or peripheral arterial disease with concomitant use of clopidogrel and/or aspirin, based upon the findings of the TRA 2°P-TIMI 50 trial. However, Vorapaxar was also found to have a significantly increased risk of bleeding, which must be considered when administering this drug. Based upon further subgroup analysis of both the TRA 2°P-TIMI 50 trial and TRACER trial, Vorapaxar was found to be potentially beneficial in patients with peripheral artery disease, coronary artery bypass grafting, and ischemic stroke. There are current trials in progress that are further evaluating the use of Vorapaxar in those conditions, and future research and trials are necessary to fully determine the utility of this drug.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...